Hologic, Inc. (HOLX) All Metrics
HOLX Valuation Metrics
HOLX Stock Price Metrics
HOLX Dividend Metrics
HOLX Growth Rate Metrics
HOLX Discounted Cash Flow Metrics
| Fair Value Price | $108.60 |
| Margin of Safety | 42.88% |
HOLX Revenue Metrics
HOLX PE Ratio Metrics
| PE Ratio | 31.67 |
| PE Ratio Avg TTM | 28.12 |
| PE Ratio Avg 3Y | 30.08 |
| Current VS TTM Avg | +12.61% |
| Current VS 3Y Avg | +5.29% |
| Current VS 5Y Avg | +38.75% |
HOLX PS Ratio Metrics
| PS Ratio | 4.16 |
| PS Ratio Avg TTM | 3.83 |
| PS Ratio Avg 3Y | 4.27 |
| Current VS TTM Avg | +8.65% |
| Current VS 3Y Avg | -2.66% |
| Current VS 5Y Avg | +4.39% |
HOLX PB Ratio Metrics
| PB Ratio | 3.27 |
| PB Ratio Avg TTM | 3.17 |
| PB Ratio Avg 3Y | 3.48 |
| Current VS TTM Avg | +3.01% |
| Current VS 3Y Avg | -5.93% |
| Current VS 5Y Avg | -13.53% |
HOLX Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 17.18 |
| PFCF Ratio Avg TTM | 16.11 |
| PFCF Ratio Avg 3Y | 18.13 |
| Current VS TTM Avg | +6.66% |
| Current VS 3Y Avg | -5.22% |
| Current VS 5Y Avg | +17.95% |
HOLX Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.52 |
| Debt/Equity Ratio Avg TTM | 0.52 |
| Debt/Equity Ratio Avg 3Y | 0.55 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | -6.31% |
| Current VS 5Y Avg | -24.46% |
HOLX PEG Ratio Metrics
| PEG Ratio | 0.30 |
| PEG Ratio Avg TTM | 0.30 |
| PEG Ratio Avg 3Y | 0.30 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
HOLX FCF Yield
| FCF Yield | 5.82% |
| FCF Yield Avg TTM | 6.30% |
| FCF Yield Avg 3Y | 5.70% |
| Current VS TTM Avg | -7.64% |
| Current VS 3Y Avg | +2.08% |
| Current VS 5Y Avg | -26.19% |
HOLX Earnings Yield
| Earnings Yield | 3.16% |
| Earnings Yield Avg TTM | 3.63% |
| Earnings Yield Avg 3Y | 3.48% |
| Current VS TTM Avg | -12.85% |
| Current VS 3Y Avg | -9.09% |
| Current VS 5Y Avg | -43.68% |
HOLX EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 24.28 |
| Ev/Ebit Ratio Avg TTM | 22.66 |
| Ev/Ebit Ratio Avg 3Y | 24.05 |
| Current VS TTM Avg | +7.17% |
| Current VS 3Y Avg | +0.94% |
| Current VS 5Y Avg | +32.53% |
HOLX EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 17.28 |
| Ev/Ebitda Ratio Avg TTM | 15.01 |
| Ev/Ebitda Ratio Avg 3Y | 15.35 |
| Current VS TTM Avg | +15.14% |
| Current VS 3Y Avg | +12.54% |
| Current VS 5Y Avg | +39.24% |
HOLX EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.91 |
| Ev/Assets Ratio Avg TTM | 1.84 |
| Ev/Assets Ratio Avg 3Y | 1.98 |
| Current VS TTM Avg | +3.57% |
| Current VS 3Y Avg | -3.55% |
| Current VS 5Y Avg | -8.36% |
HOLX EV/Sales Ratio Metrics
| Ev/Sales Ratio | 4.25 |
| Ev/Sales Ratio Avg TTM | 4.02 |
| Ev/Sales Ratio Avg 3Y | 4.39 |
| Current VS TTM Avg | +5.84% |
| Current VS 3Y Avg | -3.21% |
| Current VS 5Y Avg | +2.31% |
HOLX Current Ratio Metrics
| Current Ratio | 3.75 |
| Current Ratio Avg TTM | 3.72 |
| Current Ratio Avg 3Y | 3.76 |
| Current VS TTM Avg | +0.81% |
| Current VS 3Y Avg | -0.20% |
| Current VS 5Y Avg | +17.13% |
HOLX Quick Ratio Metrics
| Quick Ratio | 3.06 |
| Quick Ratio Avg TTM | 3.04 |
| Quick Ratio Avg 3Y | 3.12 |
| Current VS TTM Avg | +0.49% |
| Current VS 3Y Avg | -2.00% |
| Current VS 5Y Avg | +14.97% |
HOLX ROIC Metrics
| ROIC | 7.35% |
| ROIC Avg 3Y | 9.78% |
| ROIC Avg 5Y | 13.56% |
| Current VS 3Y Avg | -24.83% |
| Current VS 5Y Avg | -45.81% |
| Current VS 10Y Avg | -22.42% |
HOLX Return on Assets Metrics
| ROA | 6.28 |
| ROA Avg TTM | 7.45 |
| ROA Avg 3Y | 8.56 |
| Current VS TTM Avg | -15.70% |
| Current VS 3Y Avg | -26.64% |
| Current VS 5Y Avg | -46.72% |
HOLX Return on Equity Metrics
| ROE | 11.21 |
| ROE Avg TTM | 13.30 |
| ROE Avg 3Y | 15.60 |
| Current VS TTM Avg | -15.71% |
| Current VS 3Y Avg | -28.13% |
| Current VS 5Y Avg | -54.54% |
HOLX Net Profit Margin Metrics
| Net Profit Margin | 13.80% |
| Net Profit Margin Avg TTM | 16.70% |
| Net Profit Margin Avg 3Y | 17.87% |
| Current VS TTM Avg | -17.34% |
| Current VS 3Y Avg | -22.76% |
| Current VS 5Y Avg | -38.31% |
Last Updated: Wednesday, June 10, 2026
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini